# Cochrane

# Trusted evidence.

# Informed decisions.

# Library

# Better health.

# Zhao 2020

Zhao HL, Chen SZ, Xu HM, Zhou YL, He J, Huang HL, et al. Efficacy and safety of fecal microbiota transplantation for treating patients with ulcerative colitis: a systematic review and meta-analysis. Journal of Digestive Diseases 2020;21(10):534-48.

# References to other published versions of this review

# Imdad 2017

Imdad A, Nicholson MR, Tanner-Smith EE, Zackular JP, Gomez-Duarte O, Borromeo Beaulieu DM, et al. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database of Systematic Reviews 2017, Issue 8. Art. No: CD012774. [DOI: 10.1002/14651858.CD012774]

# Imdad 2018

Imdad A, Nicholson MR, Tanner-Smith EE, Zackular JP, Gomez-Duarte OG, Beaulieu DB, et al. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database of Systematic Reviews 2018, Issue 11. Art. No: CD012774. [DOI: 10.1002/14651858.CD012774.pub2]

* Indicates the major publication for the study

# CHARACTERISTICS OF STUDIES

# Characteristics of included studies [ordered by study ID]

# Březina 2021

# Study characteristics

# Methods

Multicenter, open-label RCT conducted in the Czech Republic

# Participants

# Inclusion criteria

- Adults age < 70 years, with clinically and endoscopically active left-sided UC for > 3 months, total Mayo score 4–10, and endoscopy subscore ≥ 2
- Participants were allowed to use oral 5-ASA (stable dose for 8 weeks, maximal dose 4 g), thiopurines (stable dose for 8 weeks), and oral prednisone (≤ 10 mg daily, stable for 4 weeks), if they maintained same dosage during study period

# Exclusion criteria

- Use of anti-TNF medication and other biologic therapy in preceding 12 weeks, rectal corticosteroids or 5-ASA in preceding 4 weeks, calcineurin inhibitors in preceding 12 weeks, methotrexate in preceding 8 weeks, prednisone > 10 mg, antibiotics or probiotics in preceding 8 weeks
- Indeterminate colitis, CD, IBS, impending risk of colectomy, history of bowel cancer
- Positive stool culture for Salmonella, Shigella, Yersinia, Campylobacter, pathogenic Escherichia coli; cytomegalovirus infection, Clostridioides difficile infection
- Pregnancy, lactation

# Interventions

# Experimental arm

n = 23

- Single donor feces (multiple donors recruited for study but each participant received feces from 1 donor only)
- 50 g of stool in 150–170 mL infusion per treatment; administered via enema; 5 times in the first week and then once weekly for 5 more weeks

# Control arm

n = 22

- Mesalamine 4 g; administered via enema; daily for 2 weeks and then every other day until end of week 6

# Outcomes

# Primary outcome

Clinical remission at week 12 (total Mayo score ≤ 2 with no subscore > 1)

Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.